3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
36
Gynecologic
19
Genitourinary
19
Tumor-Agnostic
11
Other solid neoplasm
11
Gastrointestinal
10
Thoracic
9
Other hematologic neoplasm
7
CNS
4
Sarcoma
3
Myeloid
2
Lymphoid
2
Head & Neck
2
Endocrine
2
Plasma cell
1
NET
1
Classical hematology
1
Conditions
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Interventions
Dexamethasone
871
Bortezomib
457
Lenalidomide
456
Cyclophosphamide
365
Melphalan
272
Calcium Dobesilate
263
daratumumab
234
pomalidomide
208
carfilzomib
182
fludarabine phosphate
140
fludarabine
136
Thalidomide
125
Peripheral Blood Stem Cell Transplantation
119
Filgrastim
114
ixazomib
93
Mycophenolic Acid
90
Granulocyte Colony-Stimulating Factor
89
Whole-Body Irradiation
87
Busulfan
87
dexamethasone acetate
86
Tacrolimus
78
dexamethasone 21-phosphate
74
isatuximab
69
Cyclosporine
68
auricularum
67
Prednisone
65
elotuzumab
58
belantamab mafodotin
57
Antilymphocyte Serum
56
Etoposide
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
talazoparib
×
Plasma cell
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled